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Stereotactic Radiotherapy 
 
 
Introduction  
 
Stereotactic ablative radiotherapy (SABR or SBRT) is routinely used for the treatment of 
early stage peripheral lung cancer and is increasingly used to treat other primary or 
metastatic tumour sites [1-9]. There are currently a number of UK studies open to 
recruitment (of which 3 are randomised trials) investigating the utility of SABR in the 
treatment of oligometastatic disease (breast, lung, and prostate), lung, prostate, pancreas 
and hepatobiliary primary malignancies[10-13]. These are supported by Cancer Research 
UK (CRUK) and further studies are in development. In addition, a NHS Commissioning 
through Evaluation (CtE) programme was commenced in 2015 to evaluate SABR in 
situations where clinical trials are not available [14]. 
 
The focus of many of these studies is the use of SABR in the treatment of oligometastatic 
disease. Inherent in the delivery of SABR to oligometastatic sites at any location in the body 
is an understanding of the local normal tissue dose constraints. It is recognised that as 
SABR is a relatively new treatment technique, definitively established dose constraints which 
directly correlate to risk of toxicity are rare. However, in order to standardise protocols and 
the associated radiotherapy planning, members of the various trial management groups 
collaborated to generate a consensus document on appropriate organ at risk (OAR) dose 
constraints associated with the various common SABR fractionations. 
 
There are numerous publications which report toxicity following SABR at various sites. 
These have been summarised in a number of reports or reviews [15-18]. The most 
comprehensive of these reviews is the AAPM-101 report [16], but this is now over 5 years 
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old, and newer data are available. Rather than conduct a primary systemic review, the 
values contained within the AAPM-101 report were revised where appropriate, by taking into 
consideration any updated or more robust data on a given dose constraint value in the 
opinion of the panel, as described below.   
 
 
General principles of dose constraint selection and application to 
clinical trials or routine practice 
 
In choosing the most appropriate dose constraints for UK SABR treatments, the following 
principles in selecting and applying these dose constraints have been used: 
 
1.) Both optimal and mandatory dose constraints were included, where appropriate; 
 
2.) For body (extra-cranial) dose constraints, except for the spinal cord/canal, a near-point 
maximum dose volume of 0.5 cc should be used across sites. This represents a volume 
which is both clinically realistic and comparable when calculated across different planning 
systems. For cranial regions, and the spinal canal as a surrogate for cord dose in most 
cases, a near-point maximum dose volume of 0.1 cc should be used. It should be noted that 
where the area to be treated abuts the spinal cord, the spinal cord should be explicitly 
defined on both CT and MRI, and a margin for set-up errors added based on local 
specification; 
 
3.) There are differences in the ways dose constraints are reported for serial and parallel 
organs. Care should be taken to distinguish between these and the key principles are listed 
in Figure 1. 
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4.) For the purpose of these guidelines, single fraction treatment should not be given extra-
cranially. 3 or 5 fraction regimes are recommended, along with 8 fractions for selected 
thoracic lesions; 
 
5.) Radiation Therapy Oncology Group (RTOG) normal tissue atlases should be used for 
delineation of OARs [19]. Specifically it is recommended to follow the RTOG guidance by 
contouring the spinal canal based on the bony limits of the spinal canal. The spinal cord 
should be contoured starting at the level just below cricoid (or at the level of the base of skull 
for tumour of the lung apex) and continuing on every CT slice to the bottom of L2.  Neural 
foraminae should not be included; 
 
6.) The dose constraints described in this document are only applicable for patients receiving 
SABR alone. For patients who have received recent or are receiving concomitant systemic 
therapy (and in particular anti-angiogenic agents and other biological agents) there may be 
an enhanced risk of normal tissue toxicity;  
 
7.) These dose constraints are not applicable to re-irradiation of the same organ using 
SABR, except where another part of the organ (e.g. lung or liver) has incidentally previously 
received standard fractionation radiotherapy on a previous occasion; 
 
8.) Where 2 separate GTVs are being treated in the same organ (e.g. two separate lung 
metastases) during the same treatment course, then the summed dose to both lesions and 
associated OARs should not usually exceed the given dose constraints; 
 
9.) Where patients are having more than one lung lesion treated with SABR, it is 
recommended that these should be treated on alternate days and with the same 
dose/fractionation (usually the most conservative schedule). The use of alternate day 
treatments reduces the dose per fraction to the whole lung, and is recommended in an effort 
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to limit the risk of severe pneumonitis and fibrosis. Both sites may be treated on the same 
day is if the tumours can be encompassed in a single field, for small metastases in otherwise 
fit patients, or when the combined percentage of lung volume receiving a dose of 20Gy or 
higher (V20 Gy) is below the tolerance for a single lesion. There is little published data on 
normal tissue tolerances for multiple lesions and ideally the standard thoracic constraints 
should be met. However, the OAR constraint which is most likely to be exceeded is the V20 
Gy. In the case of treating two or three lung lesions, the following V20 Gy lung constraints 
should be followed: 
 
o Optimal                                                  <12.5% 
o Acceptable in all cases     <15%  
o Acceptable in selected cases with good lung function <20% 
 
Where the lung function parameters of forced expiratory volume in 1 second (FEV1) and 
transfer factor (DLCO) are below 40% of predicted, its strongly recommended that the V20 
Gy should be kept below 12.5% (optimal) or 15% (mandatory). 
 
10.) Where patients are having more than one liver metastasis treated with SABR, it is 
recommended a 5 fractions regime is used and that all OAR constraints should be met as 
per single lesion, with at least 40 hours (alternate days) between treatments. 
 
11.) These dose constraints are to be used as guidance only. Those using these dose 
constraints should note that the final responsibility for radiotherapy plan evaluation remains 
with the treating clinician and the treating institution. Changes should be justified using good 
a priori medical reasons. 
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12.) These constraints will be reviewed as part of biennial updates to the UK SABR 
Consortium guidelines.  
 
 
 
Specific principles for each anatomical site grouping 
 
CNS (Table 1) ± These constraints are primarily based on those described in the AAPM-101 
report[16], with some modification to give consistent near-point maximum dose volumes for 
serial organs (0.1 cc), and taking account of recent risk analyses for optics and spinal cord 
[20,21]. Cochlea volumes are usually so small than the mean dose may be considered as 
the near-point dose, and an optimal limit has been added to reflect recent studies [22]. 
Optimal limits have also been added for lens and orbit (as a surrogate for retina), though 
these should generally be kept as low as reasonable practicable. Single fraction treatments 
are recommended for CNS metastases, but multi-fraction constraints are also included for 
large lesions, or in the rare event of skull bone metastases receiving SABR treatment. These 
constraints are not specifically designed for stereotactic radiosurgery (SRS), but may be 
useful in this regard also. However some centres have used higher tolerances successfully, 
or sought to spare other structures such as trigeminal nerve. 
 
Thoracic (Table 2) ± For 3 and 5 fractions schedules, as well as Optimal values for 8 
fraction schedules, updated constraints are taken from the UK SABR consortium guidelines 
[18], which were based on those used in the ROSEL trial [23] and VU Amsterdam practice. 
For 8 fraction Mandatory constraints, those used in the LungTech trial [24] have been 
adopted. These, in turn, were based on the treatment strategies for 8 fraction SABR for 
central lung cancers (i.e. those within 2cm of main airways or proximal bronchial tree) as 
described by Haasbeek et al [25] and shaped by additional information from trials and 
clinical practice [24,26,27]. The LungTech protocol describes dose constraints for all OARs 
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except the heart and great vessels, where UK SABR consortium constraints have been 
adopted for both Optimal and Mandatory values [18]. When delineating the proximal 
bronchial tree, defined as the most inferior 2 cm of distal trachea and the proximal airways 
on both sides, both mediastinal and lung windows on CT should be used, as appropriate to 
each case. )RU ³XOWUD-FHQWUDO´ WXPRXUV LH those adjacent to the hilar structures, with GTV 
directly abutting a main bronchus [28], there is still uncertainty regarding the OAR tolerances 
for SABR given concerns about significant toxicity. A recent updated version of the 
LungTech protocol has allowed higher doses the proximal bronchial tree for those tumours 
whose PTV is near or abutting the wall of the proximal bronchial tree. In this scenario a 
subvolume is delineated of the adjacent proximal bronchial tree that is allowed to have 60Gy 
in 8 fractions.  Therefore we would recommend a cautious approach for central and 
particularly ultra-central tumours and patients should be consented for the potential 
increased risk of toxicity. Such patients should be treated in a clinical trial or in a prospective 
evaluation programme. 
 
Gastro-Intestinal and Abdomen (Table 3) ± For five fraction schedules, updated 
constraints are taken from the ABC-07 trial and the SPARC study [13,29]. These constraints 
incorporate revised AAPM-101 constraints in light of published trials data [30-32] and do not 
apply for cirrhotic liver. For three fraction schedules, constraints are those described by the 
AAPM-101 report [16], with additional liver constraints from other early SABR work [33-35]. 
The ABC-07 and SPARC trials do not include a rectal constraint and so both 3 and 5 fraction 
constraints are those reported by AAPM-101 [16]. For lower lobe lung treatments, significant 
irradiation of the abdominal structures is not a common clinical occurrence where co-planar 
delivery is employed. If there is a risk of significant irradiation of an adjacent intra-abdominal 
organ (e.g. liver for right lower lobe lung tumours), then imaging of the entire organ should 
occur at simulation.  
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Pelvis and Other (Table 4) ± Updated constraints are available from the PACE trial (5 
fractions) [12], however these apply specifically to primary treatment of the prostate which 
allows potentially higher bowel toxicity that would be acceptable from treatment to a 
metastatic site. Therefore, the AAPM-101 constraints are retained for pelvic treatments in 
general [16], with the addition of the ureteric constraints as used in the BR001 trial of SABR 
for multiple metastases [36]. The PACE study dose constraints are included separately for 
interest [12]. More recently, prospective data from North America has provided further insight 
into rectal tolerances in SABR, including the impact of patient-related factors [37,38]. These 
data also relate to the primary treatment of the prostate, and so may not be appropriate in 
other, non-radical settings. Optimal constraints on the skin are included based on AAPM-101 
values [16]. 
 
Discussion 
 
This document presents the current UK consensus on OAR constraints for the delivery of 
SABR. These are largely based on the constraints reported in the AAPM-101 report from 
2010 [16], with modification based on newer data and/or current clinical trial protocols, 
which, in turn, have also been shaped by more recent data. While many of these constraints 
have already been adopted in clinical practice with low rates of severe toxicity, it must be 
remembered that the total number of patients treated with SABR is relatively low (particularly 
in the setting of SABR for sites other than peripheral lung cancer), and follow-up data is 
relatively immature. As such, the constraints presented here are not necessarily definitive 
but form a unified strategy for going forward. On-going prospective evaluation of treated 
patients, with documentation of toxicities and dosimetric analysis remain essential for future 
refinement of constraints as required. The adoption of a consistent set of constraints and 
fractionation schedules across the UK should facilitate the efficient management of this 
process.  
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While it is perhaps considered reassuring to adopt constraints from within a formal report 
such as that of the AAPM, it is also important to note that the constraints within the AAPM-
101 report are not based on extensive clinical outcome data, but represent the constraints 
published by two centres based on limited clinical experience DQG HYHQ ³HGXFDWHG
JXHVVZRUN´ [16], again underlining the importance of on-going prospective data collection. 
Any existing constraints, including those presented here, are not definitive but should be 
considered work in progress. Additional evidence from both UK and international studies, 
along with suggested constraints from other groups [37-39] may be used to further refine 
values in the future. 
 
The more traditional OAR constraints for conventionally fractionated radiotherapy produced 
by Emami et al are quoted with reference to specific toxicity outcomes and the associated 
magnitudes of risk of those endpoints (e.g TD 5/5 represents a 5% risk of a specific 
complication at 5 years) [40]. Quantification of risk is unquestionably helpful in clinical 
practice, both when evaluating plans and discussing treatments with patients. However, 
because of the nature by which many of the existing SABR constraints were derived, such 
clinical end-point data is frequently unavailable. Therefore, in this current report we are not 
able to accompany many of the clinical endpoints with the magnitude of the risks of those 
endpoints. A comprehensive review of clinically adopted SABR constraints, together with the 
numbers of patients experiencing severe toxicity for each different set of constraints, was 
previously published by Grimm et al in 2011 and forms a highly useful complimentary 
resource [41]. More recently, an entire volume of Seminars of Radiation Oncology was 
devoted to the modelling and reporting of normal tissue toxicity for SABR treatments[38]. 
Different constraints were generated based on a range of large and small volumes, and on 
both high and low risks of each endpoint. Level of acceptable risk varied depending on the 
severity of the outcome. For example, chest wall (rib fracture) constraints still correlate with a 
50% or 5% risk of this complication, but for a critical structure like spinal cord (myelitis) risks 
of 3% and 1% would be more appropriate [42]. The AAPM-101 Stereotactic Body 
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Radiotherapy Working Group required that reported constraints were published in the peer-
reviewed literature, while the work presented in Seminars in Radiation Oncology included 
new data and dose response modelling [42], thus facilitating the presentation of constraints 
for higher and lower risk situations and risk quantifications for multiple fractionation 
schedules, albeit with the uncertainties that accompany any modelling process. Despite the 
different approaches in generating constraints to this current report, the constraints 
presented are not dissimilar, which is reassuring. Both sets of constraints, however, require 
on-going clinical validation. 
 
A further area of uncertainty in determining SABR organ at risk constraints is the impact of 
individual patient-related factors, such as previous surgeries, diabetes, smoking, heavy 
previous exposure to cytotoxic agents or patients at the extremes of age. Incorporation of 
novel agents either before or after SABR is becoming more common, and will also have a 
significant effect on toxicity [43]. It is currently unknown how such factors should be 
incorporated into constraint determination for SABR, although some groups of patients have 
been identified as being at higher risk of certain complications [37]. Intuitively, more 
conservative constraints may well be more appropriate in patients who might be considered 
at increased risk of toxicity, as is already recommended for V20 Gy in patients with poor lung 
function (general point 9 above), and those with underlying liver cirrhosis [39]. Patient-
related factors should therefore also be prospectively recorded, alongside dosimetry and 
outcomes, to guide future modification of constraints, including the potential integration of 
patient-specific factors. 
 
It is recognised that longer delivery times are associated with superior biological 
effectiveness in the setting of head and neck cancer [44]. How treatment delivery duration 
impacts on outcomes in patients receiving SABR is less well documented. Many linac-based 
centres deliver SABR using VMAT and FFF, in an effort to keep treatment times short. The 
delivery of SABR using the Cyberknife results in much longer delivery times than associated 
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with repair mechanisms, however there is little evidence that control rates are any lower with 
this modality. For future analysis, it would be useful to record treatment duration to allow 
investigation as to whether this has an impact on outcome.  
 
Importantly, the constraints presented in this document are intended for a first course of 
SABR to a previously non-irradiated site. For patients who have received previous 
radiotherapy, the uncertainties in re-irradiation normal tissue tolerance are substantial. 
SABR re-irradiation has, however, been successfully delivered to oligometastases, with 
encouraging rates of local control and low rates of high grade toxicity in small and 
heterogeneous series [45,46]. Most study to date has been devoted to the re-irradiation 
tolerance of the spinal cord, but even then, patient numbers are relatively low [46,47]. As 
such, determining SABR re-irradiation constraints is an area for future research and is 
beyond the scope of this current report.  
 
Going forward in the UK, therefore, the priorities are to use the constraints presented here in 
clinical practice and trials, together with high quality prospective data collection and 
dosimetric analysis to guide future modification if necessary. It is hoped that the use of a 
unified set of constraints and fractionation schedules across the UK will facilitate the efficient 
and effective validation of these constraints.  
 
 
Conclusion 
A national agreement on SABR dose constraints has been achieved. It is hoped that this 
unified approach will facilitate standardised implementation of SABR across the UK and will 
permit meaningful toxicity comparisons between SABR studies and further refinement of the 
constraints. Further SABR trials developed in the UK will aim to adopt this consensus. 
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Manuscript with Changes shown - UK Consensus on Normal Tissue 
Dose Constraints for Stereotactic Radiotherapy 
 
CHANGES ILLUSTRATED IN RED FONT 
Introduction  
 
Stereotactic ablative radiotherapy (SABR or SBRT) is routinely used for the treatment of 
early stage peripheral lung cancer and is increasingly used to treat other primary or 
metastatic tumour sites [1-9]. There are currently a number of UK studies open to 
recruitment (of which 3 are randomised trials) investigating the utility of SABR in the 
treatment of oligometastatic disease (breast, lung, and prostate), lung, prostate, pancreas 
and hepatobiliary primary malignancies[10-13]. These are supported by Cancer Research 
UK (CRUK) and further studies are in development. In addition, a NHS Commissioning 
through Evaluation (CtE) programme was commenced in 2015 to evaluate SABR in 
situations where clinical trials are not available [14]. 
 
The focus of many of these studies is the use of SABR in the treatment of oligometastatic 
disease. Inherent in the delivery of SABR to oligometastatic sites at any location in the body 
is an understanding of the local normal tissue dose constraints. It is recognised that as 
SABR is a relatively new treatment technique, definitively established dose constraints which 
directly correlate to risk of toxicity are rare. However, in order to standardise protocols and 
the associated radiotherapy planning, members of the various trial management groups 
collaborated to generate a consensus document on appropriate organ at risk (OAR) dose 
constraints associated with the various common SABR fractionations. 
 
There are numerous publications which report toxicity following SABR at various sites. 
These have been summarised in a number of reports or reviews [15-18]. The most 
comprehensive of these reviews is the AAPM-101 report [16], but this is now over 5 years 
Manuscript with Changes shown
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old, and newer data are available. Rather than conduct a primary systemic review, the 
values contained within the AAPM-101 report were revised where appropriate, by taking into 
consideration any updated or more robust data on a given dose constraint value in the 
opinion of the panel, as described below.   
 
 
General principles of dose constraint selection and application to 
clinical trials or routine practice 
 
In choosing the most appropriate dose constraints for UK SABR treatments, the following 
principles in selecting and applying these dose constraints have been used: 
 
1.) Both optimal and mandatory dose constraints were included, where appropriate; 
 
2.) For body (extra-cranial) dose constraints, except for the spinal cord/canal, a near-point 
maximum dose volume of 0.5 cc should be used across sites. This represents a volume 
which is both clinically realistic and comparable when calculated across different planning 
systems. For cranial regions, and the spinal canal as a surrogate for cord dose in most 
cases, a near-point maximum dose volume of 0.1 cc should be used. It should be noted that 
where the area to be treated abuts the spinal cord, the spinal cord should be explicitly 
defined on both CT and MRI, and a margin for set-up errors added based on local 
specification; 
 
3.) There are differences in the ways dose constraints are reported for serial and parallel 
organs. Care should be taken to distinguish between these and the key principles are listed 
in Figure 1. 
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4.) For the purpose of these guidelines, single fraction treatment should not be given extra-
cranially. 3 or 5 fraction regimes are recommended, along with 8 fractions for selected 
thoracic lesions; 
 
5.) Radiation Therapy Oncology Group (RTOG) normal tissue atlases should be used for 
delineation of OARs [19]. Specifically it is recommended to follow the RTOG guidance by 
contouring the spinal canal based on the bony limits of the spinal canal. The spinal cord 
should be contoured starting at the level just below cricoid (or at the level of the base of skull 
for tumour of the lung apex) and continuing on every CT slice to the bottom of L2.  Neural 
foraminae should not be included; 
 
6.) The dose constraints described in this document are only applicable for patients receiving 
SABR alone. For patients who have received recent or are receiving concomitant systemic 
therapy (and in particular anti-angiogenic agents and other biological agents) there may be 
an enhanced risk of normal tissue toxicity;  
 
7.) These dose constraints are not applicable to re-irradiation of the same organ using 
SABR, except where another part of the organ (e.g. lung or liver) has incidentally previously 
received standard fractionation radiotherapy on a previous occasion; 
 
8.) Where 2 separate GTVs are being treated in the same organ (e.g. two separate lung 
metastases) during the same treatment course, then the summed dose to both lesions and 
associated OARs should not usually exceed the given dose constraints; 
 
9.) Where patients are having more than one lung lesion treated with SABR, it is 
recommended that these should be treated on alternate days and with the same 
dose/fractionation (usually the most conservative schedule). The use of alternate day 
treatments reduces the dose per fraction to the whole lung, and is recommended in an effort 
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to limit the risk of severe pneumonitis and fibrosis. Both sites may be treated on the same 
day is if the tumours can be encompassed in a single field, for small metastases in otherwise 
fit patients, or when the combined percentage of lung volume receiving a dose of 20Gy or 
higher (V20 Gy) is below the tolerance for a single lesion. There is little published data on 
normal tissue tolerances for multiple lesions and ideally the standard thoracic constraints 
should be met. However, the OAR constraint which is most likely to be exceeded is the V20 
Gy. In the case of treating two or three lung lesions, the following V20 Gy lung constraints 
should be followed: 
 
o Optimal                                                  <12.5% 
o Acceptable in all cases     <15%  
o Acceptable in selected cases with good lung function <20% 
 
Where the lung function parameters of forced expiratory volume in 1 second (FEV1) and 
transfer factor (DLCO) are below 40% of predicted, its strongly recommended that the V20 
Gy should be kept below 12.5% (optimal) or 15% (mandatory). 
 
10.) Where patients are having more than one liver metastasis treated with SABR, it is 
recommended a 5 fractions regime is used and that all OAR constraints should be met as 
per single lesion, with at least 40 hours (alternate days) between treatments. 
 
11.) These dose constraints are to be used as guidance only. Those using these dose 
constraints should note that the final responsibility for radiotherapy plan evaluation remains 
with the treating clinician and the treating institution. Changes should be justified using good 
a priori medical reasons. 
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12.) These constraints will be reviewed as part of biennial updates to the UK SABR 
Consortium guidelines.  
 
 
 
Specific principles for each anatomical site grouping 
 
CNS (Table 1) ± These constraints are primarily based on those described in the AAPM-101 
report[16], with some modification to give consistent near-point maximum dose volumes for 
serial organs (0.1 cc), and taking account of recent risk analyses for optics and spinal cord 
[20,21]. Cochlea volumes are usually so small than the mean dose may be considered as 
the near-point dose, and an optimal limit has been added to reflect recent studies [22]. 
Optimal limits have also been added for lens and orbit (as a surrogate for retina), though 
these should generally be kept as low as reasonable practicable. Single fraction treatments 
are recommended for CNS metastases, but multi-fraction constraints are also included for 
large lesions, or in the rare event of skull bone metastases receiving SABR treatment. These 
constraints are not specifically designed for stereotactic radiosurgery (SRS), but may be 
useful in this regard also. However some centres have used higher tolerances successfully, 
or sought to spare other structures such as trigeminal nerve. 
 
Thoracic (Table 2) ± For 3 and 5 fractions schedules, as well as Optimal values for 8 
fraction schedules, updated constraints are taken from the UK SABR consortium guidelines 
[18], which were based on those used in the ROSEL trial [23] and VU Amsterdam practice. 
For 8 fraction Mandatory constraints, those used in the LungTech trial [24] have been 
adopted. These, in turn, were based on the treatment strategies for 8 fraction SABR for 
central lung cancers (i.e. those within 2cm of main airways or proximal bronchial tree) as 
described by Haasbeek et al [25] and shaped by additional information from trials and 
clinical practice [24,26,27]. The LungTech protocol describes dose constraints for all OARs 
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except the heart and great vessels, where UK SABR consortium constraints have been 
adopted for both Optimal and Mandatory values [18]. When delineating the proximal 
bronchial tree, defined as the most inferior 2 cm of distal trachea and the proximal airways 
on both sides, both mediastinal and lung windows on CT should be used, as appropriate to 
each case. )RU ³XOWUD-FHQWUDO´ WXPRXUV LH those adjacent to the hilar structures, with GTV 
directly abutting a main bronchus [28], there is still uncertainty regarding the OAR tolerances 
for SABR given concerns about significant toxicity. A recent updated version of the 
LungTech protocol has allowed higher doses the proximal bronchial tree for those tumours 
whose PTV is near or abutting the wall of the proximal bronchial tree. In this scenario a 
subvolume is delineated of the adjacent proximal bronchial tree that is allowed to have 60Gy 
in 8 fractions.  Therefore we would recommend a cautious approach for central and 
particularly ultra-central tumours and patients should be consented for the potential 
increased risk of toxicity. Such patients should be treated in a clinical trial or in a prospective 
evaluation programme. 
 
Gastro-Intestinal and Abdomen (Table 3) ± For five fraction schedules, updated 
constraints are taken from the ABC-07 trial and the SPARC study [13,29]. These constraints 
incorporate revised AAPM-101 constraints in light of published trials data [30-32] and do not 
apply for cirrhotic liver. For three fraction schedules, constraints are those described by the 
AAPM-101 report [16], with additional liver constraints from other early SABR work [33-35]. 
The ABC-07 and SPARC trials do not include a rectal constraint and so both 3 and 5 fraction 
constraints are those reported by AAPM-101 [16]. For lower lobe lung treatments, significant 
irradiation of the abdominal structures is not a common clinical occurrence where co-planar 
delivery is employed. If there is a risk of significant irradiation of an adjacent intra-abdominal 
organ (e.g. liver for right lower lobe lung tumours), then imaging of the entire organ should 
occur at simulation.  
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Pelvis and Other (Table 4) ± Updated constraints are available from the PACE trial (5 
fractions) [12], however these apply specifically to primary treatment of the prostate which 
allows potentially higher bowel toxicity that would be acceptable from treatment to a 
metastatic site. Therefore, the AAPM-101 constraints are retained for pelvic treatments in 
general [16], with the addition of the ureteric constraints as used in the BR001 trial of SABR 
for multiple metastases [36]. The PACE study dose constraints are included separately for 
interest [12]. More recently, prospective data from North America has provided further insight 
into rectal tolerances in SABR, including the impact of patient-related factors [37,38]. These 
data also relate to the primary treatment of the prostate, and so may not be appropriate in 
other, non-radical settings. Optimal constraints on the skin are included based on AAPM-101 
values [16]. 
 
Discussion 
 
This document presents the current UK consensus on OAR constraints for the delivery of 
SABR. These are largely based on the constraints reported in the AAPM-101 report from 
2010 [16], with modification based on newer data and/or current clinical trial protocols, 
which, in turn, have also been shaped by more recent data. While many of these constraints 
have already been adopted in clinical practice with low rates of severe toxicity, it must be 
remembered that the total number of patients treated with SABR is relatively low (particularly 
in the setting of SABR for sites other than peripheral lung cancer), and follow-up data is 
relatively immature. As such, the constraints presented here are not necessarily definitive 
but form a unified strategy for going forward. On-going prospective evaluation of treated 
patients, with documentation of toxicities and dosimetric analysis remain essential for future 
refinement of constraints as required. The adoption of a consistent set of constraints and 
fractionation schedules across the UK should facilitate the efficient management of this 
process.  
 
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
61 
62 
63 
64 
65 
While it is perhaps considered reassuring to adopt constraints from within a formal report 
such as that of the AAPM, it is also important to note that the constraints within the AAPM-
101 report are not based on extensive clinical outcome data, but represent the constraints 
published by two centres based on limited clinical experience DQG HYHQ ³HGXFDWHG
JXHVVZRUN´ [16], again underlining the importance of on-going prospective data collection. 
Any existing constraints, including those presented here, are not definitive but should be 
considered work in progress. Additional evidence from both UK and international studies, 
along with suggested constraints from other groups [37-39] may be used to further refine 
values in the future. 
 
The more traditional OAR constraints for conventionally fractionated radiotherapy produced 
by Emami et al are quoted with reference to specific toxicity outcomes and the associated 
magnitudes of risk of those endpoints (e.g TD 5/5 represents a 5% risk of a specific 
complication at 5 years) [40]. Quantification of risk is unquestionably helpful in clinical 
practice, both when evaluating plans and discussing treatments with patients. However, 
because of the nature by which many of the existing SABR constraints were derived, such 
clinical end-point data is frequently unavailable. Therefore, in this current report we are not 
able to accompany many of the clinical endpoints with the magnitude of the risks of those 
endpoints. A comprehensive review of clinically adopted SABR constraints, together with the 
numbers of patients experiencing severe toxicity for each different set of constraints, was 
previously published by Grimm et al in 2011 and forms a highly useful complimentary 
resource [41]. More recently, an entire volume of Seminars of Radiation Oncology was 
devoted to the modelling and reporting of normal tissue toxicity for SABR treatments[38]. 
Different constraints were generated based on a range of large and small volumes, and on 
both high and low risks of each endpoint. Level of acceptable risk varied depending on the 
severity of the outcome. For example, chest wall (rib fracture) constraints still correlate with a 
50% or 5% risk of this complication, but for a critical structure like spinal cord (myelitis) risks 
of 3% and 1% would be more appropriate [42]. The AAPM-101 Stereotactic Body 
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Radiotherapy Working Group required that reported constraints were published in the peer-
reviewed literature, while the work presented in Seminars in Radiation Oncology included 
new data and dose response modelling [42], thus facilitating the presentation of constraints 
for higher and lower risk situations and risk quantifications for multiple fractionation 
schedules, albeit with the uncertainties that accompany any modelling process. Despite the 
different approaches in generating constraints to this current report, the constraints 
presented are not dissimilar, which is reassuring. Both sets of constraints, however, require 
on-going clinical validation. 
 
A further area of uncertainty in determining SABR organ at risk constraints is the impact of 
individual patient-related factors, such as previous surgeries, diabetes, smoking, heavy 
previous exposure to cytotoxic agents or patients at the extremes of age. Incorporation of 
novel agents either before or after SABR is becoming more common, and will also have a 
significant effect on toxicity [43]. It is currently unknown how such factors should be 
incorporated into constraint determination for SABR, although some groups of patients have 
been identified as being at higher risk of certain complications [37]. Intuitively, more 
conservative constraints may well be more appropriate in patients who might be considered 
at increased risk of toxicity, as is already recommended for V20 Gy in patients with poor lung 
function (general point 9 above), and those with underlying liver cirrhosis [39]. Patient-
related factors should therefore also be prospectively recorded, alongside dosimetry and 
outcomes, to guide future modification of constraints, including the potential integration of 
patient-specific factors. 
 
It is recognised that longer delivery times are associated with superior biological 
effectiveness in the setting of head and neck cancer [44]. How treatment delivery duration 
impacts on outcomes in patients receiving SABR is less well documented. Many linac-based 
centres deliver SABR using VMAT and FFF, in an effort to keep treatment times short. The 
delivery of SABR using the Cyberknife results in much longer delivery times than associated 
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with repair mechanisms, however there is little evidence that control rates are any lower with 
this modality. For future analysis, it would be useful to record treatment duration to allow 
investigation as to whether this has an impact on outcome.  
 
Importantly, the constraints presented in this document are intended for a first course of 
SABR to a previously non-irradiated site. For patients who have received previous 
radiotherapy, the uncertainties in re-irradiation normal tissue tolerance are substantial. 
SABR re-irradiation has, however, been successfully delivered to oligometastases, with 
encouraging rates of local control and low rates of high grade toxicity in small and 
heterogeneous series [45,46]. Most study to date has been devoted to the re-irradiation 
tolerance of the spinal cord, but even then, patient numbers are relatively low [46,47]. As 
such, determining SABR re-irradiation constraints is an area for future research and is 
beyond the scope of this current report.  
 
Going forward in the UK, therefore, the priorities are to use the constraints presented here in 
clinical practice and trials, together with high quality prospective data collection and 
dosimetric analysis to guide future modification if necessary. It is hoped that the use of a 
unified set of constraints and fractionation schedules across the UK will facilitate the efficient 
and effective validation of these constraints.  
 
 
Conclusion 
A national agreement on SABR dose constraints has been achieved. It is hoped that this 
unified approach will facilitate standardised implementation of SABR across the UK and will 
permit meaningful toxicity comparisons between SABR studies and further refinement of the 
constraints. Further SABR trials developed in the UK will aim to adopt this consensus. 
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Tables 4a, b and c: Pelvic and other tissues dose constraints  
 
Organ type Principle of Dose Constraint 
Descriptor 
Example 
Serial Dose constraints are typically described 
as a threshold dose or higher that can be 
given to a small volume of the organ 
which receives the highest doses, but the 
remaining volume must be spared below 
the threshold dose. 
 
(N.B. For cumulative dose-volume 
histograms, this is equivalent to the 
maximum volume of the organ that can 
receive a threshold dose or higher). 
  
The minimum dose to the 5cc 
volume of small bowel receiving 
the highest dose should be lower 
than 25.2Gy (D5cc<25.2Gy). 
 
(equivalent to V25.2Gy<5cc) 
Parallel (Entire organ) 
(.e.g. liver, kidneys and 
lungs) 
Dose constraints are typically described 
as a maximum percentage volume of the 
organ that can receive a threshold dose 
or higher. 
  
The volume of lung receiving a 
dose of 20Gy or higher should be 
less than 10% of the total lung 
volume (V20Gy<10%). 
  
Parallel (Minimum 
critical volume of an 
organ) 
(.e.g. liver, kidneys and 
lungs) 
For these, the constraint is typically 
described as a minimum critical volume 
of the organ which must be spared from 
receiving a threshold dose (or higher). 
  
At least 200cc of kidney should 
receive a dose of 16Gy or lower  
('RVHWRFF*\). 
Figure 1
Table 1: CNS dose constraints 
 Description 
C
o
n
straint
 
1 Fraction 3 Fractions 5 Fractions 8 Fractions 
Source 
Endpoint  
(and magnitude of risk if 
previously quantified) 
O
ptim
al
 
(G
y)
 
M
andato
ry
 
(G
y)
 
O
ptim
al
 
(G
y)
 
M
andato
ry
 
(G
y)
 
O
ptim
al
 
 (G
y)
 
M
andato
ry
 
(G
y)
 
O
ptim
al
 
 (G
y)
 
M
andato
ry
 
(G
y)
 
Optic pathway DMax (0.1 cc) - < 8 - < 15 - < 22.5 - - 
AAPM[16]/ 
Hiniker[20] 
AAPM: Grade 3+ optic neuritis 
Hiniker: 3 fraction: 0.8% and 5 
fraction: 1.6% risk grade 4 
radiation-induced optic 
neuropathy when limited to 
0.05 cc 
 
Cochlea Mean < 4 < 9 - < 17.1 - < 25 - - AAPM[16]/ Tamaru[22] AAPM: Grade 3+ hearing loss 
Brainstem 
(not medulla) 
DMax 
(0.1 cc) < 10 < 15 < 18 < 23.1 < 23 < 31 - - AAPM[16] Grade 3+ cranial neuropathy 
Spinal canal* 
(inc. medulla) 
DMax 
(0.1 cc) < 10 < 14 < 18 < 21.9 < 23 < 30 < 25 < 32 
AAPM[16]/ 
Grimm[21]/ UK 
SABR 
Consortium 
[18]/ 
LungTECH[24] 
AAPM: Grade 3+ myelitis 
Grimm: single and 3# optimal 
doses to 0.1cc limit risk of 
grade 2-4 myelopathy to 
 
D1 cc < 7 - < 12.3 - < 14.5 - - -  AAPM: Grade 3+ myelitis 
 
Cauda equina & 
sacral plexus 
DMax 
(0.1 cc) - < 16 - < 24 - < 32 - - AAPM[16] Grade 3+ neuritis 
D5 cc - < 14 - < 22 - < 30 - - AAPM[16] 
Normal Brain 
(Whole Brain - 
GTV) 
D10 cc < 12 - - - - - - - Group Consensus Radiation necrosis 
Cognitive deterioration 
 D50% < 5 - - - - - - - Group Consensus 
Lens DMax (0.1 cc) < 1.5 - - - - - - - 
Group 
Consensus 
Cataract formation 
 
Tables 1-4
Orbit DMax (0.1 cc) < 8 - - - - - - - 
Group 
Consensus 
Retinopathy 
 
*For treatments of the spine itself, these constraints should be applied to the cord PRV. 
 
DMax is the near-point maximum dose, defined in this case as D0.1cc, which is the minimum dose to the 0.1cc volume of the organ receiving the highest doses. 
D1cc, D5cc and D10cc are the minimum doses to the specified volume of the organ (1cc, 5cc, 10cc) that receive the highest doses. 
D50% is the median dose to the volume (equal to the minimum dose to the 50% of the volume receiving the highest doses). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Table 2: Thoracic dose constraints 
Description  
  
 3 Fractions 5 Fractions 8 Fractions 
Source 
Endpoint (and 
magnitude of risk where 
quantified) 
O
ptim
al
 
M
a
nd
ato
ry
 
O
ptim
al
 
M
a
nd
ato
ry
 
O
ptim
al
 
 
M
a
nd
ato
ry
 
Brachial 
Plexus DMax (0.5 cc) < 24Gy < 26Gy < 27Gy < 29Gy < 27Gy < 38Gy 
3 and 5 fractions plus 
Optimal constraints 
for 8 fractions: UK 
SABR Consortium[18] 
8 fractions Mandatory 
constraints from 
LungTECH trial[24] 
(excluding heart and 
great vessels) 
Grade 3+ neuropathy 
Heart DMax (0.5 cc) < 24Gy < 26Gy < 27Gy < 29Gy < 50Gy < 60Gy 
As above 
(8 fraction heart 
constraints from UK 
SABR 
Consortium[18]) 
Grade 3+ pericarditis 
Trachea and 
bronchus DMax (0.5 cc) < 30Gy < 32Gy < 32Gy < 35Gy < 32Gy < 44Gy As above Grade 3+ stenosis/ fistula 
Normal 
Lungs*  
(Lungs-GTV) 
V20 Gy - < 10% - < 10% - < 10% As above Grade 3+ pneumonitis 
Chest Wall 
DMax (0.5 cc) < 37Gy - < 39Gy - < 39Gy - As above 
Grade 3+ fracture or pain 
D30 cc < 30Gy - < 32Gy - < 35Gy - As above 
Great 
Vessels DMax (0.5 cc) - < 45Gy - < 53Gy - - 
As above (8 fractions 
great vessels 
constraints from UK 
SABR 
Consortium[18]) 
Grade 3+ aneurysm 
*Normal Lung (Lungs-GTV) constraints for the treatment of two or three lung lesions in the same patient, should follow the guidelines in general point 9 above. 
DMax is the near-point maximum dose, defined in this case as D0.5cc, which is the minimum dose to the 0.5cc volume of the organ receiving the highest doses. 
V20 Gy is the percentage volume of the organ receiving a dose of 20Gy or higher. 
D30 cc is the minimum dose to the 30cc of the organ that receives the highest doses.
Table 3: Gastro-intestinal dose constraints 
 
Description Constraint 
3 fractions 5 fractions 
Source End point 
Optimal Mandatory Optimal Mandatory 
Duodenum 
DMax (0.5 cc) - <  22.2Gy - < 35Gy 
3 fraction: AAPM[16]           
5 fraction: ABC-07[13]/ 
SPARC protocols[28] 
Grade 3+ ulceration 
D1 cc - - < 33Gy - 
D5 cc - <  16.5Gy < 25Gy - 
D9 cc - - < 15Gy - 
D10 cc - < 11.4Gy - < 25Gy 
Stomach 
DMax (0.5 cc) - <  22.2Gy < 33Gy < 35Gy 
As above Grade 3+ ulceration/ fistulation 
D5 cc - - < 25Gy - 
D10 cc - <  16.5Gy - < 25Gy 
D50 cc - - < 12Gy - 
Small Bowel 
DMax (0.5 cc) - <  25.2Gy < 30Gy < 35Gy 
As above Grade 3+ enteritis/ 
obstruction D5 cc - <  17.7Gy < 25Gy - 
D10 cc - - - < 25Gy 
Common Bile Duct DMax (0.5 cc) < 50Gy - < 50Gy 
- As above  
Oesophagus DMax (0.5 cc) - < 25.2Gy < 32Gy 
< 34Gy 
 
(<40 Gy for 8 
fractions) 
As above plus LungTECH 
for 8 fraction schedules[24] Grade 3+ stenosis/ fistula 
Large Bowel DMax (0.5 cc) - < 28.2Gy - 
< 32Gy As above Grade 3+ colitis/ fistula 
Rectum DMax (0.5 cc) - <28.2Gy - 
<32Gy AAPM[16] Grade 3+ colitis/ fistula 
Parallel GI organs   
Normal Liver  
(Liver minus GTV) 
V10 Gy - - < 70% - 3 fraction: AAPM[16]/ Wulf 
et al[32,33]/ Rusthoven et 
al [34]               
5 fraction: ABC-07[13]/ 
SPARC [28] protocols 
Grade 3+ liver function 
dysfunction/ radiation-
induced liver disease 
(classic or non-classic) 
Mean dose - - < 13Gy < 15.2Gy 
D50% < 15Gy - - - 
'RVHWR cc < 15Gy < 19.2Gy - - 
Kidneys (individual and 
combined) 
Mean dose - - < 10Gy - 3 fraction: AAPM[16]           
5 fraction: ABC-07[13]/ 
SPARC [28]protocols Grade 3+ renal function 
dysfunction 
'RVHWR200 cc* - < 16Gy - - 
If solitary kidney or if 
one kidney mean dose 
>10Gy  
V10 Gy - - < 10% < 45% ABC-07[13]/ SPARC[28] protocols 
 
*If total kidney volume <200cc, or treating renal or adrenal lesions, then total dose to contralateral kidney should be <16Gy and aim to minimise spillage into 
ipsilateral kidney if possible. 
DMax is the near-point maximum dose, defined in this case as D0.5cc, which is the minimum dose to the 0.5cc volume of the organ receiving the highest doses. 
D1 cc, D5 cc, D9 cc, D10 cc and D50 cc are the minimum doses to the specified volume of the organ (1cc, 5cc, etc.) that receive the highest doses. 
V10 Gy is the percentage volume of the organ receiving a dose of 10Gy or higher. 
Dose to шϳϬϬ cc and ш200 cc is the maximum dose to the specified volume of the organ (700cc, 200cc) that receives the lowest doses.  
Tables 4a, b and c: Pelvic and other tissues dose constraints  
 
Table 4a: Pelvic dose constraints (for non-prostate primary irradiation) 
 Description Constraint 
3 Fractions 5 Fractions 
Source Endpoint 
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Bladder 
D15 cc - < 16.8 - < 18.3 
AAPM[16] Grade 3+ cystitis/ fistula 
DMax (0.5cc) - < 28.2 - < 38 
Penile Bulb 
D3 cc - < 21.9 - < 30 
AAPM[16] Grade 3+ impotence 
DMax (0.5cc) - < 42 - < 50 
Ureter DMax (0.5cc) - < 40 - < 45 BR001[35]  
 
DMax is the near-point maximum dose, defined in this case as D0.5cc, which is the minimum dose to the 0.5cc volume of the organ receiving the highest doses. 
D3 cc and D15 cc are the minimum doses to the specified volume of the organ (3cc, 15cc) that receive the highest doses. 
 
 
 
 
 
 
 
 
 
 
Table 4b: Other tissues dose constraints 
Description Constraint 
3 fractions 5 fractions 
Source         Endpoint 
Optimal (Gy) Optimal (Gy) 
Skin 
DMax (0.5 cc) < 33 < 39.5 
AAPM[16] Grade 3+ ulceration 
D10 cc  < 30 < 36.5 
Femoral Head D10 cc < 21.9  < 30 AAPM[16] Grade 3+ necrosis 
 
DMax is the near-point maximum dose, defined in this case as D0.5cc, which is the minimum dose to the 0.5cc volume of the organ receiving the highest doses. 
D10 cc is the minimum dose to the 10cc of the organ that receive the highest doses. 
 
Table 4c: PACE trial[12] constraints for primary prostate radiotherapy only 
 
Description  
 
Constraint 
(Prostate primary 
only) 
5 Fractions 
Source 
Optimal Mandatory 
Rectum  
D50% - < 18.1Gy 
PACE trial[12] D20% - < 29Gy 
D1 cc - < 36Gy 
Bladder  
D40% - < 18.1Gy 
As above 
V37 Gy < 5 cc < 10 cc 
Prostatic urethra (if 
visible)  D50% < 42Gy - As above 
Femoral head  D5% - < 14.5Gy As above 
Penile Bulb  D50% - < 29.5Gy As above 
Testicles  Avoid beam entry e.g. Blocking structure As above 
Bowel  D5 cc - < 18.1Gy As above D1 cc - < 30Gy 
D5%, D20%, D40% and D50% are the minimum doses to the percentage volume of the organ (5%, 20%, etc.) that receive the highest doses. D50% is equivalent 
to the median dose to the volume. 
D1cc and D5cc are the minimum doses to the specified volume of the organ (1cc, 5cc) that receive the highest doses. 
V37 Gy is the absolute volume of the organ receiving a dose of 37Gy or higher. 
 
 
 
 
 
